Bifidumbacterin, lyophilizate 5 doses 10 pcs

Pharmacotherapeutic group
Eubiotic

ATX code
A07FA

Pharmacodynamics:
Therapeutic effect of Bifidumbacterin is due to the content of live bifidobacteria in it which have antagonistic activity against a wide range of pathogenic and opportunistic microorganisms and thereby normalize the intestinal microflora improve the function of the gastrointestinal tract prevent the formation of prolonged forms of intestinal diseases.

*The content of the components of the protective drying medium in the finished product is not determined

.

Indications

Treatment and prevention of dysbacteriosis of various etiologies in children and adults. For children (including premature babies), the drug can be used from the first days of life.

For diseases of the gastrointestinal tract:

– long-term intestinal dysfunction of unknown etiology;

– acute intestinal infections (in the complex treatment of acute dysentery, salmonellosis, escherichiosis, viral diarrhea, etc.) long-term intestinal dysfunction of staphylococcal etiology, as well as treatment of convalescents after acute intestinal infections with ongoing intestinal dysfunction;

– in the complex treatment of children (including premature newborns) with pneumonia, sepsis and other purulent-infectious diseases to prevent or relieve intestinal dysfunction and prevent the development of necrotizing ulcerative enterocolitis;

– children with a burdened premorbid condition: those born prematurely or with signs of prematurity receiving antibiotics in the early neonatal period; children whose mothers suffered from severe toxicosis, extragenital diseases, had a long anhydrous period or other pathology; children of mothers with lactostasis, cracked nipples and resuming breastfeeding after recovery from mastitis; weakened children with anemia, malnutrition, rickets, diathesis and other manifestations of allergies; with whooping cough, especially if they have any intestinal dysfunction;

– with early transfer of infants to artificial feeding;

– acute and chronic inflammatory diseases of the large and small intestines (colitis, enterocolitis) in older children and adults occurring against the background of microflora disorders with deficiency or absence of bifid flora;

– intestinal dysfunctions as a result of intestinal dysbiosis resulting from long-term antibacterial hormonal radiation and other therapy during stressful situations and exposure to extreme conditions, as well as for the purpose of preventing dysbiosis;

– for the purpose of preventing mastitis for local treatment of the mammary glands of nursing mothers at risk (in women with an inverted flat nipple, a decrease in its erection, the presence of cracks) in a difficult epidemiological situation in maternity hospitals.

For diseases of the female genital area:

– in case of violation of the purity of vaginal secretions to the III-IV degree in pregnant women of the “risk” group

– for bacterial colpitis caused by staphylococcus and Escherichia coli (in monoflora or in associations) as well as for senile colpitis of a hormonal nature.

Pharmacological effect

Pharmacotherapeutic group
Eubiotic

ATX code
A07FA

Pharmacodynamics:
The therapeutic effect of Bifidumbacterin is due to the content of living bifidobacteria in it, which have antagonistic activity against a wide range of pathogenic and opportunistic microorganisms and thereby normalize the intestinal microflora, improve the activity of the gastrointestinal tract, and prevent the formation of protracted forms of intestinal diseases.

*The content of the components of the protective drying medium in the finished product is not determined

Special instructions

The drug should not be dissolved in hot water (above 40 °C).
The product is unsuitable for use if the integrity of the packaging is damaged (cracked bottles), the drug is unlabeled and has foreign inclusions.

Active ingredient

Bifidobacterium bifidum

Composition

1 dose:

Active substance: from 1×107 to 5×107 live bifidobacteria or more than 5×107 live bifidobacteria;

Excipients: components of the protective drying medium* (gelatin; sucrose (sugar); milk).

Pregnancy

The safety of this medication during pregnancy and lactation has not been studied in controlled clinical trials.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Side effects of the drug have not been established.
If side effects not mentioned in the instructions occur, you should consult your doctor.

Interaction

When taken simultaneously with chemo- and antibacterial drugs, a decrease in therapeutic effectiveness is possible.

Overdose

No cases of overdose have been reported.

Storage conditions

At temperatures from 2 to 8 °C.
Keep out of the reach of children.
Transportation conditions. At temperatures from 2 to 8 °C.

Shelf life

1 year (with contents of 1 x 107 to 5 x 107 live bifidobacteria in one dose when released).
2 years (if the release contains more than 5×107 live bifidobacteria in one dose).
A drug that has expired cannot be used.

Manufacturer

Microgen NPO, Russia